GRAIL, Inc. (GRAL) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $59.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 15%; Below-average business quality; Rich valuation.
GRAIL is a commercial-stage healthcare company selling Galleri, a blood test that screens for cancer signals from 50+ cancer types; filed a PMA with FDA in January 2026 and sold 475,000+ commercial tests through Dec 2025. Revenue comes almost entirely from Galleri test sales;... Read more
Sell if holding. Engine safety override at $59.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 15%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 60d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-12Recent Developments — GRAIL, Inc.
Latest news
- NEWS Goldman Sachs Initiates Coverage On GRAIL with Neutral Rating, Announces Price Target of $60 — benzinga Jun 5, 2026
- NEWS TD Cowen Maintains Buy on GRAIL, Raises Price Target to $69 — benzinga May 6, 2026 positive
- NEWS Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $56 — benzinga May 6, 2026 positive
- NEWS GRAIL Q1 EPS $(2.29) Beats $(2.70) Estimate, Sales $39.832M Beat $38.881M Estimate — benzinga May 5, 2026 positive
- NEWS Earnings Scheduled For May 5, 2026 — benzinga May 5, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductGalleri10-K Item 1A: 'A substantial majority of our revenue is generated from sales of Galleri and we are highly dependent on it for our success'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Volatile — 9.9% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -253.2%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $59.17: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 15%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $55.03. Score 4.5/10, moderate confidence.
Take-profit target: $77.91 (+31.7% upside). Prior stop was $55.03. Stop-loss: $55.03.
Concentration risk — Product: Galleri; Target reached (-3.0% upside); Quality below floor (2.9 < 4.0).
GRAIL, Inc. trades at a P/E of N/A (forward -6.2). TrendMatrix value score: 2.4/10. Verdict: Sell.
14 analysts cover GRAL with a consensus score of 3.9/5. Average price target: $66.
What does GRAIL, Inc. do?GRAIL is a commercial-stage healthcare company selling Galleri, a blood test that screens for cancer signals from 50+...
GRAIL is a commercial-stage healthcare company selling Galleri, a blood test that screens for cancer signals from 50+ cancer types; filed a PMA with FDA in January 2026 and sold 475,000+ commercial tests through Dec 2025. Revenue comes almost entirely from Galleri test sales; net loss was $408.4M in 2025 with $10.2B accumulated deficit largely from Illumina acquisition impairments.